![]() Frelinghuysen retired after 24 years, Ms. Trump was too much for Representative Leonard Lance, a moderate Republican who voted against the tax bill, in his effort against Mr. In the Seventh District, in the northwestern part of the state, the mere party association with Mr. Trump’s top agenda items - the newly passed federal tax law that capped the state and local tax deduction at $10,000, and the effort to repeal the Affordable Care Act - as indicative of the president’s effort to target blue states. The Democratic candidates were quick to seize on two of Mr. The president loomed over every contest in New Jersey, though the dynamic shifted slightly in the House races. “We need to make sure people feel that if we win, we’re going to represent all New Jerseyans.” “We have to recognize, to win in the future, that’s the template, that’s the blueprint,” he told supporters in Mountainside. Trump in New Jersey had grown in recent weeks. Hugin, who made it clear during the race’s only debate that he was “not a Trump Republican,” seemed to sense that the dislike of Mr. Trump.īoth candidates released ads late in the campaign that focused exclusively on the president, whose incendiary and nationalistic rhetoric on immigration as a play to his base undoubtedly backfired in New Jersey, which is among the most diverse states in the country. Hugin’s former company, the final week swung on a single issue: Mr. Menendez highlighting the cost of cancer drugs at Mr. Hugin, 64, lobbing corruption allegations and Mr. Menendez.īut in a race defined by nastiness, with Mr. Popular Democrats, like Senator Cory Booker, who also represents New Jersey, spent the days before the election campaigning relentlessly for Mr. With weeks to go and internal party polls showing the race narrowing, national Democratic groups poured more than $7 million into the state. Menendez’s seat could no longer be taken for granted, mounted a last-minute, all-out rescue effort. National and state party leaders, sensing that Mr. Still, the Democrats struggled for months to excite voters, even in districts where competitive House races had electrified the base. ![]() Menendez, 64, even found himself in a tight race in New Jersey, a state with nearly one million more registered Democrats than Republicans, was a testament to the frustrations of many voters over the ethical transgressions that led to the senator’s formal admonishment in Congress. “Tonight, we celebrate a historic moment, born of our deep belief in what we have to do to make America what it should be.”īut the race for the Senate played out quite differently. “Thank you for your vision for realizing the possibilities of the 11th District here in New Jersey,” Ms. Protests became a weekly staple outside the state offices of Republican representatives. Powerful grass-roots groups sprang from kitchen-table talks with the goal of turning congressional districts blue. ![]() Trump’s election in 2016, Democratic activists had mobilized in the state. The shift has been acute in New Jersey, where affluent suburban expanses extend out from New York City and Philadelphia. There, wealthy and well-educated whites - particularly women - who had supported Republicans for generations have recoiled against the president’s caustic language. Trump’s leadership is the erosion of support from the suburbs. “Our goal is to have something approved in the 2015 time frame,” Hugin said.At the core of the national upheaval coursing through the Republican Party as it grapples with Mr. He predicted Celgene would have an approved product in about four years time.īy the end of this year the company hopes to be conducting stem cell trials for six different uses, including Crohn’s disease, multiple sclerosis and stroke, he said. Hugin also was enthusiastic about the company’s foray into the fledgling field of stem cell research, which has yet to see a therapeutic product reach the market. Global Revlimid sales rose 39 percent to $738 million in the first quarter, and Hugin called prostate cancer “far larger than any indications that we’ve been involved in.”ĭespite advances that saw recent approvals for advanced prostate cancer drugs from Johnson & Johnson JNJ.N and Dendreon Corp DNDN.O, Hugin said there remains a dramatic need for additional therapies, calling it "a huge marketplace." The fast-growing drug is already approved to treat the blood cancer multiple myeloma and myelodysplastic syndromes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |